ferric citrate has been researched along with 25-hydroxyvitamin d 2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iguchi, A; Iino, N; Kazama, JJ; Narita, I; Watanabe, Y; Yamamoto, S; Yoshita, K | 1 |
1 other study(ies) available for ferric citrate and 25-hydroxyvitamin d 2
| Article | Year |
|---|---|
Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Anemia, Iron-Deficiency; Bone Diseases; Chelating Agents; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Sevelamer; Young Adult | 2015 |